Quantitative Estimation of Rivaroxaban in Bulk and Pharmaceutical Formulation using High-Pressure Liquid Chromatography in Reverse Phase

Download PDF

Rivaroxaban is prescribed to patients with nonvalvular atrial fibrillation to reduce the risk of stroke and blood clots in blood vessels. It is applied to the management of vascular blood clots. Goal: To create a method for estimating the dosage of Rivaroxaban in tablets and bulk using RP-HPLC that is straightforward, specific, accurate, and exact. The C18 column was used to provide the optimal circumstances. Acetonitrile: water (60:40) with pH adjusted to 4 with formic acid. Flow rate maintained at 1.0 ml/min. λ_max was detected at 249.5nm. The retention time for Rivaroxaban was found at 2.44min. Linearity was obtained in the range of 10-45μg/ml. Recovery studies were performed and %Recovery was found to be 99.91±0.1.%RSD was found to be within the limits i.e., less than 2. The correlation coefficient from the linearity plot was found to be 0.999. By considering all the results obtained, the method can be successfully applied for estimating Rivaroxaban in bulk and tablet dosage by RP-HPLC without interfering with any of the excipients and commonly used substances.